Cargando…
Developing and paying for medicines for orphan indications in oncology: utilitarian regulation vs equitable care?
Despite ‘orphan drug’ legislation, bringing new medicines for rare diseases to market and securing funding for their provision is sometimes both costly and problematic, even in the case of medicines for very rare ‘ultra orphan’ oncological indications. In this paper difficulties surrounding the intr...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
2012
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3251875/ https://www.ncbi.nlm.nih.gov/pubmed/22215105 http://dx.doi.org/10.1038/bjc.2011.544 |